Pooled five-year survival results show OS advantage for Opdivo in advanced NSCLC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Bristol-Myers Squibb Co. announced long-term pooled efficacy and safety results from the phase III CheckMate -017 and CheckMate -057 studies in patients with previously treated advanced non-small cell lung cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login